BioSpace News Archive

Haemonetics Corporation announced that it received 510 clearance from the U.S. Food and Drug Administration to expand the medical indication of its TEG® 6s Hemostasis Analyzer System for use in adult trauma settings.

Phase 1 clinical trial, expected to start in H2 2019, will be co-funded by Transgene and its collaboration partner NEC

Hansa Biopharma AB announced that the Company’s management team will participate in the following upcoming investor conferences:

Medivir AB announces that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma patients has been presented at the 2019 Society for Investigative Dermatology annual meeting in Chicago, USA.

The Permanente Federation announced that Katherine Robinson Saral will join the company as chief legal officer effective May 29, 2019.

The combination therapy, of two FDA approved drugs, protects the blood-brain-barrier and is aimed at preventing development of brain pathologies

Atlantis Healthcare, a global leader in personalised health solutions, announced the adoption of a new health psychology approach to guide development of medication adherence support programmes.

Vizient Inc. announces that Steven Lucio, PharmD, BCPS, vice president, pharmacy solutions, will present on behalf of the company and its member hospitals at the Food and Drug Administration’s (FDA) public hearing “The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products,” being held from 9 a.m. to 2:45 p.m. at the FDA White Oak Campus in Silver Spring, Maryland.

Innovus Pharmaceuticals, Inc. announced that its partner, Lavasta Pharma RFZ-LLC (“Lavasta”), a company based in Dubai, received approval from the Algerian Ministry of Health and Commerce to market and sell the Company’s Zestra® and Zestra Glide® products in that country.

First commercial sale triggers $20 million milestone payment to Exelixis